Drugs with High Abuse Potential in Modern Medicine

The Core Neurobiology of Addiction

1. Direct stimulation of dopamine neurons (e.g., nicotine via nicotinic receptors)
2. Blocking dopamine reuptake or promoting nonvesicular release (e.g., cocaine blocks DAT; amphetamines cause reverse transport)
3. Disinhibition - blocking inhibitory GABA interneurons, indirectly releasing dopamine (e.g., opioids, cannabis)

• Katzung's Basic and Clinical Pharmacology, Ch. 32, pp. 905-908

DEA Scheduling: A Clinical Guide to Abuse Potential

Class-by-Class Breakdown

1. Opioids (Schedule II - highest clinical concern)

• Intense euphoria ("rush"), especially IV or intranasal routes
• Rapid physical dependence (tolerance within days-weeks)
• Severe, highly aversive withdrawal syndrome drives compulsive use (negative reinforcement)
• Fentanyl is 50-100x more potent than morphine; illicit analogues (carfentanil) are even more dangerous

2. Psychostimulants (Schedule I-II)

Cocaine (Schedule II)

• Mechanism: Blocks dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT) → massive dopamine surge in NAc
• Also a local anesthetic (Na+ channel blocker) - the only drug with this dual property used clinically (ENT/ophthalmology)
• Highly addictive due to short half-life (30-90 min) driving binge patterns; crack cocaine (smoked) has faster onset = higher addiction potential
• No approved pharmacotherapy for cocaine use disorder as of 2025

Amphetamines / Methamphetamine (Schedule II)

• Mechanism: Reverse the dopamine transporter - actively pump dopamine OUT of presynaptic terminals, causing massive non-vesicular release. Also inhibit MAO.
• Prescribed forms: Adderall (amphetamine), Vyvanse (lisdexamfetamine), Ritalin (methylphenidate) for ADHD - DEA reports a 6.74% increase in Schedule II stimulant prescriptions in 2024 vs 2023
• Methamphetamine (crystal meth) is much more lipophilic → faster CNS penetration, longer duration, more neurotoxic (destroys dopamine and serotonin terminals)
• The ADHD medication shortage in 2025 partly reflects the massive surge in prescribing

MDMA ("Ecstasy") - Schedule I

• Primarily a serotonin releaser (also DA, NE) → empathogenic effects
• Active research as MDMA-assisted psychotherapy for PTSD (FDA granted breakthrough therapy status; Phase 3 trial data from 2023-2024 showed mixed results leading to rejection by FDA advisory panel)
• Neurotoxic to serotonergic terminals with heavy use

3. Benzodiazepines and Z-drugs (Schedule IV)

• Lower recreational "rush" than opioids/stimulants, but widespread misuse due to anxiolytic/sedative effects
• Physical dependence develops predictably with long-term use (weeks to months)
• Withdrawal can be life-threatening (seizures, delirium) - unlike opioid withdrawal which is rarely fatal
• Alprazolam (Xanax) has the highest abuse rate among benzodiazepines due to rapid onset and short half-life
• Commonly diverted; appear frequently in polydrug overdose deaths
• The Maudsley Deprescribing Guidelines emphasize that physical dependence is NOT addiction - but the withdrawal syndrome is highly challenging and often undertreated

4. Ketamine (Schedule III)

• "Special K" as a club drug - causes dissociation, out-of-body experiences, "k-hole" at high doses
• Moderate physical dependence; significant psychological dependence
• Chronic heavy use causes ketamine-induced cystitis (severe bladder damage, sometimes irreversible)
• The therapeutic boom in ketamine clinics for depression has raised new diversion concerns

5. Cannabis / THC (Schedule I federally, widely legal at state level)

• Cannabis Use Disorder affects ~9% of users (higher with daily use or adolescent onset)
• Less severe physical dependence than opioids/alcohol, but withdrawal is real (irritability, insomnia, appetite loss)
• High-THC concentrates (dabs, wax - >70% THC) have dramatically increased potency compared to 1990s cannabis
• Associated with cannabis hyperemesis syndrome and increased psychosis risk in genetically predisposed individuals
• CBD (cannabidiol) has minimal abuse potential and is FDA-approved for epilepsy

6. Nicotine (Schedule not controlled, but highly addictive)

• Binds nicotinic acetylcholine receptors (nAChRs) on VTA dopamine neurons → direct dopamine activation
• Most addictive drug by relapse rates - only ~5% of unassisted quit attempts succeed long-term
• Electronic cigarettes/nicotine pouches (ZYN, VELO) deliver nicotine without combustion - marketed as harm reduction but driving youth addiction
• Nicotine itself does not cause cancer; tobacco combustion products do

7. Alcohol (Ethanol) - Legal, not DEA-scheduled

• Multi-target: potentiates GABA-A, inhibits NMDA receptors, increases dopamine (via GABA disinhibition)
• Most prevalent substance use disorder globally
• Alcohol withdrawal is the most medically dangerous (risk of Wernicke's encephalopathy, seizures, delirium tremens - can be fatal)
• Treated with benzodiazepines (cross-tolerant via GABA-A mechanism)

8. Emerging & Modern Concerns

Why Some Drugs Have Higher Abuse Potential Than Others

1. Speed of onset - faster delivery to brain = higher addiction potential (IV > smoked > intranasal > oral)
2. Peak plasma concentration - higher peak = greater euphoria
3. Selectivity for reward circuits - drugs targeting dopamine directly (cocaine, amphetamines) vs. indirectly are generally more addictive
4. Duration of action - short-acting drugs cause more frequent dosing/bingeing (crack cocaine vs. powder; short-acting benzos vs. diazepam)
5. Route of administration - smoking/IV deliver drug to brain in 7-15 seconds
6. Individual genetic factors - only ~15-17% of cocaine users, and a similarly small fraction of opioid users, ever become addicted even with repeated exposure

Quick Reference Table